Adding bevacizumab (Avastin, Genentech) to oxaliplatin/fluoropyrimidine chemotherapy regimens for metastatic colorectal cancer can improve outcomes by roughly 10% without substantially increasing toxicity, according to a poster presentation at the American Society of Clinical Oncology?s annual Gastrointestinal Cancers Symposium.
Go to Previous Page
Go to Next Page